MET and non-small cell lung carcinoma: Eighteen NSCLC patients with EGFR mutations were identified to have c-MET amplification who developed acquired resistance to a first-generation EGFR-TKI, including 11 (61.1%) female patients and 7 (38.9%) male patients.